Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O14936

UPID:
CSKP_HUMAN

ALTERNATIVE NAMES:
Calcium/calmodulin-dependent serine protein kinase; Protein lin-2 homolog

ALTERNATIVE UPACC:
O14936; A6NES1; B7ZKY0; O43215; Q17RI4; Q59HA0; Q5VT16; Q5VT17; Q5VT18; Q5VT19; Q66T42; Q9BYH6; Q9NYB2; Q9NYB3

BACKGROUND:
The protein CASK, known for its roles in synaptic function and neural development, is a key player in the phosphotransfer from ATP to various proteins, including NRXN1. It facilitates the anchoring of synaptic transmembrane proteins and ion channel trafficking. CASK's interactions with cell-surface proteins and its participation in the LIN-10-LIN-2-LIN-7 complex highlight its multifaceted role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given CASK's critical role in diseases such as Intellectual developmental disorder with microcephaly and pontine and cerebellar hypoplasia, and FG syndrome 4, targeting this protein could lead to innovative treatments. The exploration of CASK's functions offers promising avenues for therapeutic development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.